Mounjaro vs Wegovy in Australia 2026: TGA Indications, PBS Rules & How They Differ
Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg) in Australia compared on TGA indication, PBS subsidy rules, mechanism, dose schedule and what to ask a prescriber. Service-level information only, no medicine prices. Not an advertisement and not medical advice.
10-second answer
- Wegovy is often lower-cost at maintenance dose.
- Mounjaro showed greater average weight loss in trials, but individual response varies.
- Discuss dose, tolerance and total monthly cost with a qualified prescriber.
Healthcare data note
Sources, review and limits
Main sources
- TGA medicine information
- PBS listing status
- Published Australian provider prices
- TreatCompare AU weight-loss dataset
Methodology: We compare private monthly costs, dose route, PBS status and provider checks. This page is cost comparison, not personal prescribing advice.
Important context
Healthcare prices can change without notice and may exclude consultation fees, medication, diagnostics, anaesthetic, facility fees, follow-up care or add-ons. TreatCompare summarises published or compiled pricing for comparison and planning only. Always verify the current total directly before paying.
- Source type
- TreatCompare compiled research
- Primary source
- Provider-published information and TreatCompare research
- Reporting period
- 2026-05-12
- Last updated
- 2026-05-12
- Figure type
- Mixed sources
- Use
- Research and comparison only
Are you a clinic, provider or data owner?
If you believe information on this page is inaccurate, out of date, incomplete or presented without necessary context, contact us with the page URL and supporting evidence. We review correction requests promptly, but they are not automatically accepted.
Australia hub
Australia healthcare cost guides
Australia Weight-management information
Check Australian consultation routes and prescriber safeguards
Review AHPRA registration checks, PBS context and service-level questions. This page does not compare prescription-medicine prices.
How this guide was checked
TreatCompare uses published provider fees, official regulator registers, NHS/PBS/Medicare references where relevant, and the methodology described on our methodology page. If a clinic, provider or reader spots information that is out of date, they can use our corrections page. Prices are point-in-time and can change before booking.
Most useful next step
Compare current Weight Loss options
This guide explains the costs. The Australia comparison pages show local prices, Medicare/PBS rules and next actions.
Continue from this guide
Turn this Weight Loss article into a comparison
Article visitors often need one of three routes next: provider prices, a calculator, or a related guide that narrows the decision.
Important information for Australian consumers. Tirzepatide (Mounjaro) and semaglutide 2.4mg (Wegovy) are prescription-only (Schedule 4) medicines in Australia. Australian regulations restrict the advertising of prescription medicines to consumers, so this article is general patient information about both medicines and does not display their prices or compare them on price. Suitability is a clinical decision for an AHPRA-registered prescriber following an assessment.
What this article covers
This article is a short patient-information landing comparing two TGA-approved weight-management medicines at the level of how they are regulated, dosed and prescribed in Australia — not on price.
For the full per-medicine patient information, see:
- Tirzepatide in Australia — patient information
- Semaglutide 2.4mg in Australia — patient information
- Comparing weight-management treatment pathways in Australia
Both medicines in summary
| Tirzepatide (Mounjaro) | Semaglutide 2.4mg (Wegovy) | |
|---|---|---|
| Class | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| Dosing rhythm | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Dose escalation | Stepwise escalation under prescriber supervision | Stepwise escalation under prescriber supervision |
| TGA indication | Weight management (Australian Register of Therapeutic Goods) | Weight management (Australian Register of Therapeutic Goods) |
| PBS status (weight management) | Not currently PBS-subsidised | Not currently PBS-subsidised |
| Prescriber requirement | AHPRA-registered prescriber after clinical assessment | AHPRA-registered prescriber after clinical assessment |
What to discuss with an AHPRA-registered prescriber
- Whether either medicine is clinically appropriate given your circumstances and other medicines.
- The dose-escalation schedule and expected treatment duration.
- Monitoring requirements during treatment.
- Side effects, contraindications and interactions.
- What happens if you need to stop, and what alternatives exist.
- Service-level costs: consultation, prescription, dispensing, follow-up and (where the service uses a programme model) the programme fee.
What we do not do
We do not list prices for either medicine, do not pair a brand name with a monthly cost, do not list provider × medicine × price tables, and do not recommend a buying pathway. The medicines are priced by the dispensing pharmacy and are clinical-supply matters, not consumer-comparison products.
If you have spotted an error
Please tell us via the corrections route.
Australia hub
Australia healthcare cost guides
Frequently asked questions
What are tirzepatide and semaglutide 2.4mg?
Tirzepatide and semaglutide 2.4mg are prescription-only (Schedule 4) medicines in Australia, TGA-approved for weight management in adults who meet the clinical criteria set out in their Australian Register of Therapeutic Goods entries. They are supplied under the brand names Mounjaro and Wegovy respectively. A separate semaglutide product (Ozempic) is TGA-approved for type 2 diabetes only.
How do I choose between the two?
The choice is a clinical decision for an AHPRA-registered prescriber after a clinical assessment. Relevant factors include the TGA-approved indication, the dose-escalation schedule, side-effect profile, contraindications, interactions with your other medicines, monitoring requirements, and (for some patients) tolerance of a particular dosing rhythm.
Are either medicine PBS-subsidised for weight management?
Neither is currently PBS-subsidised for weight management in Australia. PBS schedules change; check pbs.gov.au for the current position.
Why does this page not compare them on price?
Australian regulations restrict the advertising of prescription medicines to consumers. Pairing a brand name and price in a consumer context — including a side-by-side price comparison between two medicines — is treated as advertising under the TGA Therapeutic Goods Advertising Code. We do not do that.
Get an email when prices change
Free alerts when a new provider lists, or the lower-cost published price falls. Confirm by email; unsubscribe in one click.
We'll send a confirmation link first. No marketing — alerts only. Unsubscribe with one click in any email.
Compare prices from verified providers
Weight Loss Injection Cost UK
Service-cost framework, NHS eligibility, provider checks and patient information for Mounjaro, Wegovy, Ozempic and Nevolat queries.
Lower-Cost Injection Route
NHS access, service fees and provider checks
Mounjaro Price UK Questions
Service fees, NHS access and provider checks
Wegovy Price UK Questions
Service fees, NHS access and dose context
Mounjaro Patient Information
Tirzepatide doses, safety checks and prescriber questions
Wegovy Patient Information
Semaglutide 2.4mg doses, safety checks and NHS route
Related articles
Juniper vs Mosh Australia 2026: Programme Service Comparison
General service-level comparison of Juniper and Mosh weight-management consultation routes in Australia. No prescription-medicine prices. Not an advertisement and not medical advice.
Tirzepatide in Australia: Patient Information
General patient information about tirzepatide (the active ingredient in the brand Mounjaro), a prescription-only weight-management medicine in Australia. Not an advertisement and not medical advice.
Ozempic in Australia: Patient Information
Patient information about Ozempic (semaglutide) in Australia. TGA-approved for type 2 diabetes only; the TGA has stated that promoting Ozempic for weight loss is not permitted in Australia. Not an advertisement and not medical advice.
Pilot vs Mosh Australia 2026: Programme Service Comparison
General service-level comparison of Pilot and Mosh weight-management consultation routes in Australia. No prescription-medicine prices. Not an advertisement and not medical advice.